IL-1ra delivered from poly(lactic-co-glycolic acid) microspheres attenuates IL-1β-mediated degradation of nucleus pulposus in vitro

Arthritis Research and Therapy

Volumn 14, Issue 4, 2012, Pages

  Gorth, Deborah J ^a,b   Mauck, Robert L ^a,b   Chiaro, Joseph A ^a,b   Mohanraj, Bhavana ^a   Hebela, Nader M ^b   Dodge, George R ^a,b   Elliott, Dawn M ^c   Smith, Lachlan J ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Institute University of Delaware Newark   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGGRECANASE 1; COLLAGENASE 3; GLYCOSAMINOGLYCAN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; MICROSPHERE; NITRIC OXIDE; NITRITE; POLYGLACTIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TOLL LIKE RECEPTOR 4; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; LACTIC ACID; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ARTICLE; CATABOLISM; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; IN VITRO STUDY; INTERVERTEBRAL DISK DEGENERATION; NANOFABRICATION; NUCLEOTIDE SEQUENCE; NUCLEUS PULPOSUS; PROTEIN EXPRESSION; CELL CULTURE; CHEMICALLY INDUCED; HUMAN; INTERVERTEBRAL DISC DEGENERATION; METABOLISM; PROCEDURES;

CELLS, CULTURED; DRUG DELIVERY SYSTEMS; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1BETA; INTERVERTEBRAL DISC DEGENERATION; LACTIC ACID; MICROSPHERES; POLYGLYCOLIC ACID;

EID: 84864499507     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3932     Document Type: Article

References (52)

1. Andersson GBJ. Epidemiological features of chronic low-back pain. Lancet 1999, 354:581-585. 10.1016/S0140-6736(99)01312-4, 10470716.
2. Bogduk N. The lumbar disc and low back pain. Neurosurg Clin N Am 1991, 2:791-806.
3. Freemont AJ. The cellular pathobiology of the degenerate intervertebral disc and discogenic back pain. Rheumatology (Oxford) 2009, 48:5-10.
4. Smith LJ, Nerurkar NL, Choi KS, Harfe BD, Elliott DM. Degeneration and regeneration of the intervertebral disc: lessons from development. Dis Model Mech 2011, 4:31-41. 10.1242/dmm.006403, 3008962, 21123625.
5. Urban JPG, Roberts S. Degeneration of the intervertebral disc. Arthritis Res Ther 2003, 5:120-130. 165040, 12723977.
6. Adams MA, McNally DS, Dolan P. 'Stress' distributions inside intervertebral discs. The effects of age and degeneration. J Bone Joint Surg Br 1996, 78:965-972. 10.1302/0301-620X78B6.1287, 8951017.
7. Roughley PJ. Biology of intervertebral disc aging and degeneration: involvement of the extracellular matrix. Spine 2004, 29:2691-2699. 10.1097/01.brs.0000146101.53784.b1, 15564918.
8. Hoyland JA, Le Maitre C, Freemont AJ. Investigation of the role of IL-1 and TNF in matrix degradation in the intervertebral disc. Rheumatology (Oxford) 2008, 47:809-814.
9. Le Maitre CL, Freemont AJ, Hoyland JA. The role of interleukin-1 in the pathogenesis of human intervertebral disc degeneration. Arthritis Res Ther 2005, 7:R732-745. 10.1186/ar1732, 1175026, 15987475.
10. Le Maitre CL, Hoyland JA, Freemont AJ, Le Maitre CL, Hoyland JA, Freemont AJ. Catabolic cytokine expression in degenerate and herniated human intervertebral discs: IL-1beta and TNFalpha expression profile. Arthritis Res Ther 2007, 9:R77. 10.1186/ar2275, 2206382, 17688691.
11. Le Maitre CL, Pockert A, Buttle DJ, Freemont AJ, Hoyland JA. Matrix synthesis and degradation in human intervertebral disc degeneration. Biochem Soc Trans 2007, 35:652-655. 10.1042/BST0350652, 17635113.
12. Pockert AJ, Richardson SM, Le Maitre CL, Lyon M, Deakin JA, Buttle DJ, Freemont AJ, Hoyland JA. Modified expression of the ADAMTS enzymes and tissue inhibitor of metalloproteinases 3 during human intervertebral disc degeneration. Arthritis Rheum 2009, 60:482-491. 10.1002/art.24291, 19180493.
13. Le Maitre CL, Freemont AJ, Hoyland JA. Human disc degeneration is associated with increased MMP 7 expression. Biotech Histochem 2006, 81:125-131. 10.1080/10520290601005298, 17129995.
14. Le Maitre CL, Freemont AJ, Hoyland JA. Localization of degradative enzymes and their inhibitors in the degenerate human intervertebral disc. J Pathol 2004, 204:47-54. 10.1002/path.1608, 15307137.
15. Mirza SK, Deyo RA. Systematic review of randomized trials comparing lumbar fusion surgery to nonoperative care for treatment of chronic back pain. Spine (Phila Pa 1976) 2007, 32:816-823.
16. Smith LJ, Chiaro JA, Nerurkar NL, Cortes DH, Horava SD, Hebela NM, Mauck RL, Dodge GR, Elliott DM. Nucleus pulposus cells synthesize a functional extracellular matrix and respond to inflammatory cytokine challenge following long-term agarose culture. Eur Cell Mater 2011, 22:291-301. 3424069, 22102324.
17. Braddock M, Quinn A. Targeting IL-1 in inflammatory disease: new opportunities for therapeutic intervention. Nat Rev Drug Discov 2004, 3:330-339. 10.1038/nrd1342, 15060528.
18. Arend WP. Interleukin 1 receptor antagonist. A new member of the interleukin 1 family. J Clin Invest 1991, 88:1445-1451. 10.1172/JCI115453, 295645, 1834696.
19. Chevalier X, Giraudeau B, Conrozier T, Marliere J, Kiefer P, Goupille P. Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: a multicenter study. J Rheumatol 2005, 32:1317-1323.
20. Chevalier X, Goupille P, Beaulieu AD, Burch FX, Bensen WG, Conrozier T, Loeuille D, Kivitz AJ, Silver D, Appleton BE. Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2009, 61:344-352. 10.1002/art.24096, 19248129.
21. Fleischmann R, Stern R, Iqbal I. Anakinra: an inhibitor of IL-1 for the treatment of rheumatoid arthritis. Expert Opin Biol Th 2004, 4:1333-1344.
22. Fleischmann RM, Schechtman J, Bennett R, Handel ML, Burmester GR, Tesser J, Modafferi D, Poulakos J, Sun G. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial. Arthritis Rheum 2003, 48:927-934. 10.1002/art.10870, 12687534.
23. Kavanaugh A. Anakinra (interleukin-1 receptor antagonist) has positive effects on function and quality of life in patients with rheumatoid arthritis. Adv Ther 2006, 23:208-217. 10.1007/BF02850127, 16751154.
24. Mertens M, Singh JA. Anakinra for rheumatoid arthritis: a systematic review. J Rheumatol 2009, 36:1118-1125. 10.3899/jrheum.090074, 19447938.
25. Caron JP, Fernandes JC, Martel-Pelletier J, Tardif G, Mineau F, Geng C, Pelletier JP. Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis. Suppression of collagenase-1 expression. Arthritis Rheum 1996, 39:1535-1544. 10.1002/art.1780390914, 8814066.
26. Goupille P, Mulleman D, Chevalier X, Goupille P, Mulleman D, Chevalier X. Is interleukin-1 a good target for therapeutic intervention in intervertebral disc degeneration: lessons from the osteoarthritic experience. Arthritis Res Ther 2007, 9:110. 10.1186/ar2324, 2246235, 18086327.
27. Sive JI, Baird P, Jeziorsk M, Watkins A, Hoyland JA, Freemont AJ. Expression of chondrocyte markers by cells of normal and degenerate intervertebral discs. Mol Pathol 2002, 55:91-97. 10.1136/mp.55.2.91, 1187156, 11950957.
28. Le Maitre CL, Hoyland JA, Freemont AJ. Interleukin-1 receptor antagonist delivered directly and by gene therapy inhibits matrix degradation in the intact degenerate human intervertebral disc: an in situ zymographic and gene therapy study. Arthritis Res Ther 2007, 9:R83. 10.1186/ar2282, 2206387, 17760968.
29. Nerlich AG, Schaaf R, Walchli B, Boos N. Temporo-spatial distribution of blood vessels in human lumbar intervertebral discs. Eur Spine J 2007, 16:547-555. 10.1007/s00586-006-0213-x, 2229818, 16947015.
30. Prescribing Information: Kineret (Anakinra). 2009, Thousand Oaks, CA: Amgen.
31. Pisal DS, Kosloski MP, Balu-Iyer SV. Delivery of therapeutic proteins. J Pharm Sci 2010, 99:2557-2575. 10.1002/jps.22054, 2857543, 20049941.
32. Zanette D, Dundon W, Soffientini A, Sottani C, Marinelli F, Akeson A, Sarubbi E. Human IL-1 receptor antagonist from Escherichia coli: large-scale microbial growth and protein purification. J Biotechnol 1998, 64:187-196. 10.1016/S0168-1656(98)00111-4, 9821675.
33. Cohen S, Yoshioka T, Lucarelli M, Hwang LH, Langer R. Controlled delivery systems for proteins based on poly(lactic/glycolic acid) microspheres. Pharm Res 1991, 8:713-720. 10.1023/A:1015841715384, 2062800.
34. Yang YY, Chia HH, Chung TS. Effect of preparation temperature on the characteristics and release profiles of PLGA microspheres containing protein fabricated by double-emulsion solvent extraction/evaporation method. J Control Release 2000, 69:81-96. 10.1016/S0168-3659(00)00291-1, 11018548.
35. Johnstone B, Hering TM, Caplan AI, Goldberg VM, Yoo JU. In vitro chondrogenesis of bone marrow-derived mesenchymal progenitor cells. Exp Cell Res 1998, 238:265-272. 10.1006/excr.1997.3858, 9457080.
36. Soltz MA, Ateshian GA. Experimental verification and theoretical prediction of cartilage interstitial fluid pressurization at an impermeable contact interface in confined compression. J Biomech 1998, 31:927-934. 10.1016/S0021-9290(98)00105-5, 9840758.
37. Farndale RW, Sayers CA, Barrett AJ. A direct spectrophotometric microassay for sulfated glycosaminoglycans in cartilage cultures. Connect Tissue Res 1982, 9:247-248. 10.3109/03008208209160269, 6215207.
38. Stegemann H, Stalder K. Determination of hydroxyproline. Clin Chim Acta 1967, 18:267-273. 10.1016/0009-8981(67)90167-2, 4864804.
39. Nimni ME. Collagen: structure, function, and metabolism in normal and fibrotic tissues. Semin Arthritis Rheum 1983, 13:1-86. 10.1016/0049-0172(83)90024-0, 6138859.
40. Fitzgerald JB, Jin M, Grodzinsky AJ. Shear and compression differentially regulate clusters of functionally related temporal transcription patterns in cartilage tissue. J Biol Chem 2006, 281:24095-24103. 10.1074/jbc.M510858200, 16782710.
41. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008, 3:1101-1108. 10.1038/nprot.2008.73, 18546601.
42. Shive MS, Anderson JM. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev 1997, 28:5-24. 10.1016/S0169-409X(97)00048-3, 10837562.
43. Kaiser C, Knight A, Nordstrom D, Pettersson T, Fransson J, Florin-Robertsson E, Pilstrom B. Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations. Rheumatol Int 2012, 32:295-299. 10.1007/s00296-011-2096-3, 3264859, 21881988.
44. Urban JP, Smith S, Fairbank JC. Nutrition of the intervertebral disc. Spine 2004, 29:2700-2709. 10.1097/01.brs.0000146499.97948.52, 15564919.
45. Lavi G, Voronov E, Dinarello CA, Apte RN, Cohen S. Sustained delivery of IL-1 Ra from biodegradable microspheres reduces the number of murine B16 melanoma lung metastases. J Control Release 2007, 123:123-130. 10.1016/j.jconrel.2007.07.015, 17900737.
46. van de Weert M, Hennink WE, Jiskoot W. Protein instability in poly(lactic-co-glycolic acid) microparticles. Pharmaceut Res 2000, 17:1159-1167.
47. Moioli EK, Hong L, Guardado J, Clark PA, Mao JJ. Sustained release of TGFbeta3 from PLGA microspheres and its effect on early osteogenic differentiation of human mesenchymal stem cells. Tissue Eng 2006, 12:537-546. 10.1089/ten.2006.12.537, 16579687.
48. Razaq S, Wilkins RJ, Urban JPG. The effect of extracellular pH on matrix turnover by cells of the bovine nucleus pulposus. Eur Spine J 2003, 12:341-349. 10.1007/s00586-003-0582-3, 12883962.
49. Kitano T, Zerwekh JE, Usui Y, Edwards ML, Flicker PL, Mooney V. Biochemical changes associated with the symptomatic human intervertebral disk. Clin Orthop Relat Res 1993, 372-377.
50. Mauck RL, Seyhan SL, Ateshian GA, Hung CT. Influence of seeding density and dynamic deformational loading on the developing structure/function relationships of chondrocyte-seeded agarose hydrogels. Ann Biomed Eng 2002, 30:1046-1056.
51. Takeda K, Akira S. TLR signaling pathways. Semin Immunol 2004, 16:3-9. 10.1016/j.smim.2003.10.003, 14751757.
52. Wuertz K, Vo N, Kletsas D, Boos N. Inflammatory and catabolic signalling in intervertebral discs: the roles of NF-kappaB and MAP kinases. Eur Cell Mater 2012, 23:103-119. discussion 119-120.